<DOC>
	<DOCNO>NCT01176032</DOCNO>
	<brief_summary>The purpose study assess efficacy aliskiren reduce circulating level biomarkers leave ventricular ( LV ) remodel associate LV hypertrophy ( LVH ) hypertensive patient .</brief_summary>
	<brief_title>ALiskiren Losartan Effects bioMARKers Myocardial Remodeling</brief_title>
	<detailed_description>Blood pressure measure 10 week start treatment ( visit 3 ) . All patient achieve require blood pressure ( &lt; 140/90 mmHg ) 8 week treatment maximum dos study medication give 5 mg amlodipine addition study medication order reach require BP ( &lt; 140/90 mmHg ) . The patient 's blood pressure assess visit 4 ( week 18 ) still require level ( &lt; 140/90 mmHg ) , dose amlodipine increase 10 mg . Blood pressure assess visit 5 ( week 26 ) require value reach ( &lt; 140/90 mmHg ) , 12.5 mg dose hydrochlorothiazide ( HCTZ ) prescribe</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patient hypertension Confirmed concentric leave ventricular hypertrophy : LVMI &gt; 49.2 g/m2.7 men &gt; 46.7 g/m2.7 woman Relative wall thickness &gt; 0.42 Sever secondary HTN LV ejection fraction &lt; 40 % Patient compelling indication ACEIs ARBs BB History myocardial infarction , coronary artery bypass surgery , PTC intervention , TIA stroke within 6 month study entry History collagenopathies , osteopathy eGFR &lt; 30 ml/min/1,73 m2 , serum potassium ≥5,2 mEq/L Morbid obesity ( BMI ≥ 42 kg/m2 Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Aliskiren</keyword>
	<keyword>hypertension</keyword>
	<keyword>concentric LVH</keyword>
	<keyword>LV remodel</keyword>
	<keyword>LVMI</keyword>
	<keyword>biomarkers</keyword>
	<keyword>PICP</keyword>
	<keyword>CT-1</keyword>
	<keyword>MMP-1</keyword>
	<keyword>TIMP-1</keyword>
	<keyword>AnxA5</keyword>
	<keyword>Aldosterone</keyword>
	<keyword>Essential hypertension concentric leave ventricle hypertrophy</keyword>
</DOC>